Evidence map›Paper›PMID 35814860›Full record

ArticleAdvances in radiation oncology

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.

Eric K Nguyen, Aly Khan A Lalani, Sunita Ghosh, Naveen S Basappa, Anil Kapoor, Aaron R Hansen, Christian Kollmannsberger, Daniel Heng, Lori A Wood, Vincent Castonguay and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Eric K NguyenMcMaster University, Hamilton, Ontario, Canada.
Aly Khan A LalaniMcMaster University, Hamilton, Ontario, Canada.
Sunita GhoshCross Cancer Institute, Edmonton, Alberta, Canada.
Naveen S BasappaCross Cancer Institute, Edmonton, Alberta, Canada.
Anil KapoorMcMaster University, Hamilton, Ontario, Canada.
Aaron R HansenPrincess Margaret Cancer Centre-University of Toronto, Toronto, Ontario, Canada.
Christian KollmannsbergerBC Cancer Agency, Vancouver, British Columbia, Canada.
Daniel HengTom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Lori A WoodDalhousie University, Halifax, Nova Scotia, Canada.
Vincent CastonguayUniversite Laval, Quebec City, Quebec, Canada.
Denis SoulièresCentre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Eric WinquistWestern University, London, Ontario, Canada.
Christina CanilThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
Jeffrey GrahamUniversity of Manitoba, Winnipeg, Manitoba, Canada.
Georg A BjarnasonSunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Rodney H BreauThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
Frédéric PouliotUniversite Laval, Quebec City, Quebec, Canada.
Anand SwaminathMcMaster University, Hamilton, Ontario, Canada.
McMaster University · CAAlberta Cancer Foundation · CAUniversité Laval · CAUniversity of Ottawa · CABC Cancer Agency · CACentre Hospitalier de l’Université de Montréal · CADalhousie University · CASunnybrook Health Science Centre · CAUniversity of Calgary · CAUniversity of Manitoba · CAUniversity of Toronto · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: With the integration of immunotherapy (IO) agents in the management of metastatic renal cell carcinoma (mRCC), there has been interest in the combined use with radiation therapy (RT). However, real world data are limited. The purpose of this study was to evaluate outcomes in patients with mRCC receiving both RT and IO compared with IO alone. Methods and Materials: Data were collected from Canadian Kidney Cancer Information System from January 2011 to September 2019 across 14 academic centers. Patients with mRCC who received IO as first- or second-line therapy were included. RT was categorized as radical dose or palliative dose. Kaplan-Meier estimates were reported for overall survival (OS) and time to treatment failure. Cox proportional hazard models were used adjusted for age and International Metastatic RCC Database Consortium risk categories. Results: In total, 505 patients were included in the study: 179 received RT + IO and 326 received IO alone. Two-year OS for the RT + IO group was 55.0% compared with 66.4% in the IO alone cohort (adjusted hazard ratio [aHR], 1.38; Conclusions: In this descriptive analysis, more than one-third of patients with mRCC received RT and demonstrated inferior outcomes compared with IO alone. Potential explanations include greater presence of adverse metastatic sites in those receiving RT. Prospective clinical trials evaluating potential benefits of RT in an IO era remain an important need.

Identifiers

PMID35814860
PMCPMC9260099
OpenAlexW4205304319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.